Tiffany Chou

Tiffany Chou is currently working as a Scientist at Tallac Therapeutics since May 2022. In this role, they are the primary scientist and independent lead on ELISA assay development efforts for clinical and nonclinical programs. Tiffany also analyzes samples from non-clinical toxicology and PK/PD studies and collaborates with research and development teams on other relevant bioassays.

Before joining Tallac Therapeutics, Tiffany worked as a Scientist II at Kodiak Sciences from September 2021 to May 2022.

Prior to that, they were a Senior Research Associate at Encoded Therapeutics Inc. from April 2019 to September 2021.

Tiffany started their career as an Associate Scientist II at AbbVie from June 2017 to April 2019.

Tiffany then worked as a Research Associate II at Regeneron Pharmaceuticals, Inc. from December 2014 to June 2017.

Tiffany's earlier work experience includes positions as a Staff Scientist and an Associate Scientist at QPS, LLC from May 2014 to November 2014 and June 2012 to May 2014, respectively.

Tiffany Chou attended Penn State University from 2007 to 2011, where they obtained a Bachelor of Science (B.S.) degree in Biology, General.